CCXI Profile
ChemoCentryx Inc (CCXI) is a biopharmaceutical company that focuses on discovering, developing, and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer. The company's lead drug candidate is Avacopan, an oral, selective complement 5a receptor inhibitor that is being evaluated in Phase III clinical trials for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis) and C3 glomerulopathy (C3G), both of which are rare autoimmune diseases. The company is headquartered in California, United States.
|
